Bone loss in survival motor neuron (Smn−/−SMN2) genetic mouse model of spinal muscular atrophy
- 14 April 2009
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 219 (1), 52-60
- https://doi.org/10.1002/path.2566
Abstract
Spinal muscular atrophy (SMA) is characterized by degenerating lower motor neurons and an increased incidence of congenital bone fractures. Survival motor neuron (SMN) levels are significantly reduced due to deletions/mutations in the telomeric SMN1 gene in these patients. We utilized the Smn−/− SMN2 mouse model of SMA to determine the functional role for SMN in bone remodelling. µCT analysis of lumber vertebrae, tibia and femur bones from SMA mice revealed an osteoporotic bone phenotype. Histological analysis demonstrated a thin porous cortex of cortical bone and thin trabeculae at the proximal end of the growth plate in the vertebrae of SMA mice compared to wild‐type mice. Histochemical staining of the vertebrae showed the presence of abundant activated osteoclasts on the sparse trabeculae and on the endosteal surface of the thin cortex in SMA mice. Histomorphometric analysis of vertebrae from SMA mice showed an increased number of osteoclasts. Serum TRAcP5b and urinary NTx levels were elevated, consistent with increased bone resorption in these mice. SMA mice showed a significant decrease in the levels of osteoblast differentiation markers, osteocalcin, osteopontin and osterix mRNA expression; however, there were no change in the levels of alkaline phosphatase expression compared to WT mice. SMA mouse bone marrow cultures revealed an increased rate of osteoclast formation (54%) and bone resorption capacity (46%) compared to WT mice. Pre‐osteoclast cells from SMA mice showed constitutive up‐regulation of RANK receptor signalling molecules critical for osteoclast differentiation. Our results implicate SMN function in bone remodelling and skeletal pathogenesis in SMA. Understanding basic mechanisms of SMN action in bone remodelling may uncover new therapeutic targets for preventing bone loss/fracture risk in SMA. Copyright © 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Funding Information
- National Institutes of Health (C06 RR015455)
This publication has 28 references indexed in Scilit:
- Hypercalcaemia in infancy; a presenting feature of spinal muscular atrophyArchives of Disease in Childhood, 2004
- Cytokine Regulation and the Signaling Mechanism of Osteoclast Inhibitory Peptide-1 (OIP-1/hSca) to Inhibit Osteoclast FormationJournal of Bone and Mineral Research, 2003
- Severe Spinal Muscular Atrophy Variant Associated With Congenital Bone FracturesJournal of Child Neurology, 2002
- Identification of the Functional Domain of Osteoclast Inhibitory Peptide-1/hScaJournal of Bone and Mineral Research, 2002
- Osteoclast-stimulating Factor Interacts with the Spinal Muscular Atrophy Gene Product to Stimulate Osteoclast FormationOnline Journal of Public Health Informatics, 2001
- SMN oligomerization defect correlates with spinal muscular atrophy severityNature Genetics, 1998
- Identification and characterization of a mouse homologue of the Spinal Muscular Atrophy-determining gene, survival motor neuronGene, 1997
- Synergistic anti-apoptotic activity between Bcl-2 and SMN implicated in spinal muscular atrophyNature, 1997
- Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryosProceedings of the National Academy of Sciences of the United States of America, 1997
- Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committeeJournal of Bone and Mineral Research, 1987